Mersana Therapeutics to Present at Jefferies London Healthcare Conference

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ: MRSN) announced that its management will present at the Jefferies London Healthcare Conference on November 15, 2022, at 3:50 p.m. GMT (10:50 a.m. ET). The presentation can be accessed via a live webcast on the company's website, with an archived replay available for 90 days. Mersana is focused on developing innovative antibody-drug conjugates (ADCs) targeting cancers, with its lead candidate, upifitamab rilsodotin (UpRi), in various clinical trials for ovarian cancer.

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 3:50 p.m. GMT (10:50 a.m. ET).

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the event.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was named among the 2021 Top Places to Work in Massachusetts by The Boston Globe. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

When will Mersana Therapeutics present at the Jefferies London Healthcare Conference?

Mersana Therapeutics will present on November 15, 2022, at 3:50 p.m. GMT (10:50 a.m. ET).

How can I watch the Mersana Therapeutics presentation from the Jefferies London Healthcare Conference?

The presentation will be available via a live webcast on Mersana's website in the Investors & Media section.

What is Mersana Therapeutics focusing on in their clinical pipeline?

Mersana Therapeutics is focused on developing antibody-drug conjugates (ADCs) for treating various cancers, particularly through their lead candidate UpRi.

What is the lead product candidate of Mersana Therapeutics?

Mersana's lead product candidate is upifitamab rilsodotin (UpRi), targeting NaPi2b in ovarian cancer.

What clinical trials is Mersana Therapeutics conducting with UpRi?

UpRi is involved in several trials, including UPLIFT, UPGRADE, and UP-NEXT, focusing on different patient populations with ovarian cancer.